CDC slides suggest ‘positive surprise’ for GSK, says Goldman Sachs

Goldman Sachs says the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices published its final agenda ahead of its rescheduled February meeting being held on April 15-16. Information provided within the respiratory syncytial virus older adult slides indicates the majority of the working group recommend RSV vaccine intervention to those aged 50-59 years at increased risk, the analyst tells investors in a research note. Goldman believes the slides suggest the committee will likely vote to expand its recommended population for GSK‘s (GSK) Arexvy to those aged 50-59. This would represent a “positive surprise” for GSK, contends the firm.